Patents Assigned to Genset S.A.
-
Publication number: 20030162186Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.Type: ApplicationFiled: May 22, 2002Publication date: August 28, 2003Applicant: GENSET, S.A.Inventors: Stephane Bejanin, Hiroaki Tanaka
-
Publication number: 20030157485Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.Type: ApplicationFiled: November 13, 2001Publication date: August 21, 2003Applicant: GENSET, S.A.Inventors: Stephane Bejanin, Hiroaki Tanaka
-
Publication number: 20030148389Abstract: The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.Type: ApplicationFiled: February 6, 2002Publication date: August 7, 2003Applicant: GENSET, S.A.Inventors: Bernard Bihain, Barbara Bour, Lydie Bougueleret
-
Publication number: 20030118997Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.Type: ApplicationFiled: October 15, 2001Publication date: June 26, 2003Applicant: GENSET, S.A.Inventors: Stephane Bejanin, Hiroaki Tanaka
-
Patent number: 6582909Abstract: The invention provides novel APM1 genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the APM1 locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Additionally, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. Further, the invention provides diagnostic methods for early detection of obesity-related disorders.Type: GrantFiled: May 10, 2000Date of Patent: June 24, 2003Assignee: Genset, S.A.Inventors: Lydie Bougueleret, Bernard Bihain, Blake Denison, Frances Yen-Potin
-
Patent number: 6579852Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: July 19, 2001Date of Patent: June 17, 2003Assignee: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Publication number: 20030108882Abstract: The present invention is directed to a polynucleotide comprising open reading frames defining a coding region encoding a retinoblastoma binding protein (RBP-7) as well as regulatory regions located both at the 5′ end and the 3′ end of said coding region. The present invention also pertains to a polynucleotide carrying the natural regulation signals of the RBP-7 gene which is useful in order to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory region. The invention also concerns polypeptides encoded by the coding region of the RBP-7 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.Type: ApplicationFiled: March 19, 2002Publication date: June 12, 2003Applicant: GENSET, S.A.Inventor: Lydie Bougueleret
-
Patent number: 6573068Abstract: The sequence of a cDNA encoding Claudin-50 and sequence of Claudin-50 protein are disclosed. The cDNA can be used to express the protein or portions thereof or to obtain antibodies capable of specifically binding to the secreted protein. The cDNA may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNA may also be used to design expression vectors and secretion vectors.Type: GrantFiled: September 15, 2000Date of Patent: June 3, 2003Assignee: Genset, S. A.Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret
-
Publication number: 20030099989Abstract: The present invention relates to fluorescent probes which can be used in multicolor fluorescence in situ hybridization, and mainly chromosome painting. The probes intended for labeling a chromosome are such that they are composed of a set of DNA segments which are more represented in certain chromosome bands and which are obtained by IRS-PCR amplification from said chromosomes using PCR primers specific for the repeated and dispersed Alu and LINE DNA sequences.Type: ApplicationFiled: September 19, 2002Publication date: May 29, 2003Applicant: Genset, S.A.Inventor: Dorra Cherif
-
Publication number: 20030100500Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: ApplicationFiled: August 29, 2002Publication date: May 29, 2003Applicant: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen, Bernard Bihain
-
Publication number: 20030099965Abstract: The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.Type: ApplicationFiled: June 20, 2002Publication date: May 29, 2003Applicant: GENSET, S.A.Inventor: Lydie Bougueleret
-
Publication number: 20030096247Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.Type: ApplicationFiled: November 14, 2001Publication date: May 22, 2003Applicant: GENSET, S.A.Inventors: Stephane Bejanin, Hiroaki Tanaka
-
Patent number: 6566332Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: February 5, 2001Date of Patent: May 20, 2003Assignee: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen, Bernard Bihain
-
Publication number: 20030092011Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.Type: ApplicationFiled: November 14, 2001Publication date: May 15, 2003Applicant: GENSET, S.A.Inventors: Stephane Bejanin, Hiroaki Tanaka
-
Publication number: 20030092620Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.Type: ApplicationFiled: July 22, 2002Publication date: May 15, 2003Applicant: GENSET, S.A.Inventors: John Lucas, Kristen Briggs
-
Patent number: 6559294Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.Type: GrantFiled: November 23, 1998Date of Patent: May 6, 2003Assignee: Genset, S.A.Inventors: Remy Griffais, Susan K. Hoiseth, Robert John Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah Diane Fletcher
-
Patent number: 6555316Abstract: The invention concerns the human g35030 gene, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the g35030 gene and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.Type: GrantFiled: October 3, 2000Date of Patent: April 29, 2003Assignee: Genset S.A.Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Laurent Essioux
-
Patent number: 6551792Abstract: The present invention concerns, in particular, human flavin-containing monooxygenase 2 (hFMO2), and another human enzyme of the FMO, hFMOx family, their nucleotide and polypeptide sequences. The present invention also concerns vectors for cloning and/or expression containing said nucleotide sequences and cells transformed by these vectors and method for preparing said polypeptides. The invention further concerns methods for selecting compounds and of diagnosing predisposition to pathologies and/or deficiencies related to FMO's and pharmaceutical compositions containing said compounds for treating and/or preventing these pathologies.Type: GrantFiled: June 4, 1999Date of Patent: April 22, 2003Assignees: Genset, S.A., Institute National de la Sante et de la Recherche MedicaleInventors: Marta Blumenfeld, Ilia Tchoumakov, Henri-Jean Garchon, Jean-Francois Bach
-
Patent number: 6548633Abstract: The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.Type: GrantFiled: June 21, 2000Date of Patent: April 15, 2003Assignee: Genset, S.A.Inventors: Jean-Baptiste Dumas Milne Edwards, Lydie Bougueleret, Severin Jobert
-
Patent number: 6544737Abstract: The invention concerns the genomic sequence of the purH gene. The invention also concerns biallelic markers of a purH gene and the association established between these markers and cancer, particularly prostate cancer. The invention provides means to determine the predisposition of individuals to cancer as well as means for the diagnosis of cancer and for the prognosis/detection of an eventual treatment response to agents acting on cancer.Type: GrantFiled: March 23, 2000Date of Patent: April 8, 2003Assignee: Genset S.A.Inventors: Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret, Annick Cohen-Akenine